Gentium SpA PT Raised to $38.00 at Brean Capital (GENT)
Stock analysts at Brean Capital upped their price target on shares of Gentium SpA (NASDAQ:GENT) from $24.00 to $38.00 in a report issued on Monday, AnalystRatings.NET reports. The firm currently has a “buy” rating on the stock. Brean Capital’s price target suggests a potential upside of 33.19% from the stock’s previous close.
Other equities research analysts have also recently issued reports about the stock. Analysts at Wedbush raised their price target on shares of Gentium SpA from $20.00 to $35.00 in a research note to investors on Monday, September 30th. They now have an “outperform” rating on the stock. Separately, analysts at Zacks downgraded shares of Gentium SpA from an “outperform” rating to a “neutral” rating in a research note to investors on Thursday, August 29th. They now have a $23.00 price target on the stock. Finally, analysts at Zacks upgraded shares of Gentium SpA from a “neutral” rating to an “outperform” rating in a research note to investors on Wednesday, July 31st. They now have a $15.70 price target on the stock.
Gentium SpA (NASDAQ:GENT) traded down 0.45% on Monday, hitting $28.53. The stock had a trading volume of 53,449 shares. Gentium SpA has a 1-year low of $6.96 and a 1-year high of $29.02. The stock has a 50-day moving average of $21.77 and a 200-day moving average of $12.41. The company has a market cap of $432.9 million and a price-to-earnings ratio of 98.15.
Gentium SpA (NASDAQ:GENT) last issued its quarterly earnings data on Tuesday, August 13th. The company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.14.
Gentium S.p.A. is a biopharmaceutical company focused on the development and manufacture of defibrotide, a drug based on single-stranded deoxyribonucleic acid (NASDAQ:GENT) derived from pig intestines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.